IR@PKUHSC  > 北京大学公共卫生学院
学科主题公共卫生
Daclizumab for relapsing remitting multiple sclerosis
Liu, Jia1; Wang, Luning1; Zhan, Si-Yan2; Xia, Yinyin3
关键词Antibodies, Monoclonal [therapeutic use] Antibodies, Monoclonal, Humanized Immunoglobulin G [therapeutic use] Immuno-suppressive Agents [therapeutic use] Multiple Sclerosis, Relapsing-Remitting [drug therapy] Humans
刊名COCHRANE DATABASE OF SYSTEMATIC REVIEWS
2012
DOI10.1002/14651858.CD008127.pub3
4
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
资助者Department of Geriatric Neurology, Chinese PLA General Hospital, China ; Department of Geriatric Neurology, Chinese PLA General Hospital, China
研究领域[WOS]General & Internal Medicine
关键词[WOS]DIAGNOSTIC-CRITERIA ; MONOCLONAL-ANTIBODY ; IN-VIVO ; CELLS ; GUIDELINES ; THERAPY
英文摘要

Background

The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. Moreover, there are no severe safety concerns arising from clinical testing so far.

Objectives

To assess the efficacy and safety of daclizumab for the clinical progression of patients with relapsing remitting multiple sclerosis.

Search methods

We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group′s Trials Register (February 2012), MEDLINE (January 1966 to February 2012), EMBASE (January 1985 to February 2012). At the same time, we handsearched the references quoted in the identified trials reports (February 2012) from the most important neurological associations and MS Societies. Contacts with researchers participating in trials on daclizumab have been established.

Selection criteria

All randomized controlled clinical trials (RCTs) evaluating daclizumab, alone or combined with other treatments versus placebo, or any other treatment for patients with RRMS.

Data collection and analysis

Two review authors independently assessed references retrieved for possible inclusion. Disagreements regarding inclusion were resolved by consensus. We contacted study authors for additional information. We collected adverse effects information from the trials.

Main results

We identified 470 references from all electronic databases searched excluding duplicate. After screening of titles and abstracts, full papers of 10 studies were obtained and assessed for eligibility. An additional ongoing trial was found. Only one trial (230 participants) evaluating the efficacy of daclizumab versus placebo in interferon beta treated patients was included. It was judged as of high quality study. No significant difference was found in the expanded disability score changes and the annualised relapse rate comparing treated versus placebo groups. No significant difference of common adverse events was found across all the groups at the endpoint. The mean number of new or enlarged gadolinium contrast-enhancing lesions was significantly decreased in the interferon beta and high-dose daclizumab group, compared with that in the interferon beta and placebo group.

Authors′ conclusions

Daclizumab is well tolerated in combination with interferon beta treated multiple sclerosis population. Comparing with placebo, high-dose daclizumab can significantly decreased the number of new or enlarged gadolinium contrast-enhancing lesions. However, the evidence of recommendation is insufficient. More well-designed RCTs or crossover controlled trials are required to evaluate the efficacy and safety of daclizumab.

语种英语
资助者Department of Geriatric Neurology, Chinese PLA General Hospital, China ; Department of Geriatric Neurology, Chinese PLA General Hospital, China
WOS记录号WOS:000303012500011
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65750
专题北京大学公共卫生学院
作者单位1.Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Neurol, Beijing 100853, Peoples R China
2.Peking Univ, Ctr Evidence Based Med & Clin Res, Dept Epidemiol & Biostat, Sch Publ Hlth, Beijing 100871, Peoples R China
3.China CDC, Dept Surveilance & Stat, Natl Ctr TB Control & Prevent, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Liu, Jia,Wang, Luning,Zhan, Si-Yan,et al. Daclizumab for relapsing remitting multiple sclerosis[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS,2012(4).
APA Liu, Jia,Wang, Luning,Zhan, Si-Yan,&Xia, Yinyin.(2012).Daclizumab for relapsing remitting multiple sclerosis.COCHRANE DATABASE OF SYSTEMATIC REVIEWS(4).
MLA Liu, Jia,et al."Daclizumab for relapsing remitting multiple sclerosis".COCHRANE DATABASE OF SYSTEMATIC REVIEWS .4(2012).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Jia]的文章
[Wang, Luning]的文章
[Zhan, Si-Yan]的文章
百度学术
百度学术中相似的文章
[Liu, Jia]的文章
[Wang, Luning]的文章
[Zhan, Si-Yan]的文章
必应学术
必应学术中相似的文章
[Liu, Jia]的文章
[Wang, Luning]的文章
[Zhan, Si-Yan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。